GSS genetic signatures limited

Way undervalued

  1. 926 Posts.
    lightbulb Created with Sketch. 51
    This company has been quietly innovating the way infectious diseases are diagnosed and is set to tap into a multi-billion dollar industry demand. With only 2% of the Australian market, the company took in almost $2M in revenue with a 92% compound annual growth rate. So what is it worth if it moves to 10% of the Australian market and starts picking up US sales too?
    What if it starts to get toward 2% of the US market in the next year or so? That might mean a revenue in the order of $10M plus. This is a future $300m market cap company that is just starting to book revenue, increase sales, increase products, increase market share.
    Time to take an interest in this one.
    R
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
39.5¢
Change
0.005(1.28%)
Mkt cap ! $89.71M
Open High Low Value Volume
39.5¢ 39.5¢ 39.5¢ $304 769

Buyers (Bids)

No. Vol. Price($)
1 5000 37.5¢
 

Sellers (Offers)

Price($) Vol. No.
40.0¢ 95869 1
View Market Depth
Last trade - 11.30am 18/07/2025 (20 minute delay) ?
GSS (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.